These results suggest not only that TGF-β/SMAD axis is blocked after SMAD-4 inhibition by miR-26b-5p but also that the function of this pathway as a cell cycle regulator is affected in the CLL cells of these progressive and unmutated patients. The gene discussed is TGFB1; the disease is B-cell chronic lymphocytic leukemia.